RecruitingNCT06203652
The Pathogenesis and Prognostic Factors of Lymphoma
Sponsor
Shanghai Zhongshan Hospital
Enrollment
2,000 participants
Start Date
Jun 5, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
The aim of this study is to describe the clinical and genetic characteristics of Chinese lymphoma patients, and to explore the relationship between those characteristics and phatogenesis.
Eligibility
Inclusion Criteria3
- Patients with pathological diagnosis of lymphoma (including Hodgkin lymphoma and non-Hodgkin lyphoma, eg. THRLBCL, DLBCL, MZL, CLL/SLL...) from 2007 to 2027.
- Patients with complete diagnostic, treatment and follow-up records.
- Fully comprehension and signature of the informed consent form (ICF) for participation.
Exclusion Criteria3
- Those who refuse to use reliable methods of contraception during pregnancy, lactation or age-appropriate period.
- Severe mental illness.
- Patients deemed unsuitable for inclusion by the investigator.
Interventions
OTHERReal-world regimen
The final personalized management strategy is determined based on current conventional treatment options, physician and patient preferences.The following protocols: chemotherapy, immunochemotherapy,Anti-cd20 monoclonal antibody, BTKi and so on
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06203652
Related Trials
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
NCT0516951526 locations
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
NCT05006716120 locations
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
NCT050924511 location
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
NCT06418204467 locations
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
NCT0685942413 locations